{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:12:40Z","timestamp":1767993160336,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41431-025-01859-0","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T14:39:18Z","timestamp":1746542358000},"page":"1163-1172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predisposition to prostate cancer and clinical implications in a real-life cohort"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9093-493X","authenticated-orcid":false,"given":"Julie","family":"Chartier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-2156","authenticated-orcid":false,"given":"Albain","family":"Chansavang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-2065","authenticated-orcid":false,"given":"Anne","family":"Jouinot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadim","family":"Hamzaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunya","family":"Srikaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Moli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Tiako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-8732","authenticated-orcid":false,"given":"Mathilde","family":"Sibony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5459","authenticated-orcid":false,"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-1704","authenticated-orcid":false,"given":"Camille","family":"Tlemsani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"1859_CR1","unstructured":"Worldwide cancer data | World Cancer Research Fund International [Internet]. WCRF International. [cited 2024 Apr 7]. Available from: https:\/\/www.wcrf.org\/cancer-trends\/worldwide-cancer-data\/."},{"key":"1859_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in nordic countries. JAMA. 2016;315:68\u201376.","journal-title":"JAMA"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl J Med. 2016;375:443\u201353.","journal-title":"N. Engl J Med"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O\u2019Leary E, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523\u20138.","journal-title":"JAMA Oncol"},{"key":"1859_CR5","volume":"2018","author":"MI Carlo","year":"2018","unstructured":"Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, et al. Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the germline genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018;2018:PO.18.00060.","journal-title":"JCO Precis Oncol"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:490\u2013503.","journal-title":"J Clin Oncol"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17:479\u2013505.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.23.01868","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C, Brave MH, Bloomquist E, Fiero MH, et al. FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer. J Clin Oncol. 2024;42:605\u201313.","journal-title":"J Clin Oncol"},{"key":"1859_CR9","unstructured":"Lynparza | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza#authorisation-details."},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours. Eur Urol. 2016;70:106\u201319.","journal-title":"Eur Urol"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"1859_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0403-7","volume":"9","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln SE, Topper SE. Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation. Genome Med. 2017;9:13.","journal-title":"Genome Med"},{"key":"1859_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434\u201343.","journal-title":"Nature"},{"key":"1859_CR14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013 ;31:1748\u201357.","journal-title":"J Clin Oncol"},{"key":"1859_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT Study. Eur Urol. 2014;66:489\u201399.","journal-title":"Eur Urol"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77:24\u201335.","journal-title":"Eur Urol"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","volume":"9","author":"BF Darst","year":"2023","unstructured":"Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, et al. Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer. JAMA Oncol. 2023;9:1514\u201324.","journal-title":"JAMA Oncol"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/ijc.33024","volume":"147","author":"T Nguyen-Dumont","year":"2020","unstructured":"Nguyen-Dumont T, MacInnis RJ, Steen JA, Theys D, Tsimiklis H, Hammet F, et al. Rare germline genetic variants and risk of aggressive prostate cancer. Int J Cancer. 2020;147:2142\u20139.","journal-title":"Int J Cancer"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","volume":"4","author":"Q Karlsson","year":"2021","unstructured":"Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021;4:570\u20139.","journal-title":"Eur Urol Oncol"},{"key":"1859_CR20","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Therapeutics. 2016;15:1781\u201391.","journal-title":"Mol Cancer Therapeutics"},{"key":"1859_CR21","doi-asserted-by":"crossref","unstructured":"Hall R, Bancroft E, Pashayan N, Kote-Jarai Z, Eeles RA. Genetics of prostate cancer: a review of latest evidence. 2024 Oct [cited 2025 Mar 5]; Available from: https:\/\/jmg.bmj.com\/content\/61\/10\/915.long.","DOI":"10.1136\/jmg-2024-109845"},{"key":"1859_CR22","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.3390\/ijms21145036","volume":"21","author":"A Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci. 2020;21:5036.","journal-title":"Int J Mol Sci"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1200\/JCO.2007.14.6613","volume":"26","author":"SL Dombernowsky","year":"2008","unstructured":"Dombernowsky SL, Weischer M, Allin KH, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Risk of cancer by ATM missense mutations in the general population. J Clin Oncol. 2008;26:3057\u201362.","journal-title":"J Clin Oncol"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ng.3342","volume":"47","author":"H Helgason","year":"2015","unstructured":"Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, et al. Loss-of-function variants in ATM confer risk of gastric cancer. Nat Genet. 2015;47:906\u201310.","journal-title":"Nat Genet"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01859-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:45:48Z","timestamp":1757166348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01859-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01859-0","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was registered under the French General Data Protection Act (MR-004 French reference methodology). All patients had signed an informed consent form authorizing germline analysis and the use of data from their medical records for research. A specific information note about this study was also sent to them.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}